Medtronic Announces Scientific Data Presentations at the American Diabetes Association 80th Scientific Sessions
June 09 2020 - 3:00PM
Medtronic plc (NYSE:MDT), the global leader in medical
technology, today announced its participation at the American
Diabetes Association 80th scientific sessions virtual meeting,
June 12-16, 2020. Medtronic will be participating in this year’s
ADA virtual sessions with 16 data presentations, a symposium,
a product theater, and a virtual exhibit. Though its diverse
ADA offerings, Medtronic will showcase the company’s automated
insulin pump systems, continuous glucose monitoring (CGM) systems,
and extended-wear infusion set technology; meaningful outcomes and
differentiated support offerings, such as telehealth capabilities
and the company response to the COVID-19 pandemic.
Virtual ExhibitWith the theme of
“Innovation Beyond”, Medtronic will host a virtual exhibit booth
featuring interactive components focused on diabetes technology,
clinical outcomes, and support offerings for healthcare
professionals and patients. The exhibit will showcase current
product demonstrations, examples of real-world success with current
diabetes technologies, and an overview of Medtronic telehealth
support.
Key EventsThe data from three trials using
the next generation advanced hybrid closed loop system from
Medtronic will be presented in a symposium. Medtronic will be
participating in a product theater at this year’s conference.
Details are as follows:
- “The Next Generation of Automated Insulin Delivery System for
Persons with Type 1 Diabetes – Four New Clinical
Trials" chaired by Dr. Timothy S. Bailey on Friday, June 12,
2:00-4:00 p.m. CDT. Panelist and data to be presented will
include:
Bruce W. Bode, M.D. |
U.S. Advanced Hybrid Closed-Loop (AHCL) Pivotal Safety Study |
Richard M. Bergenstal, M.D. |
FLAIR—An NIDDK Sponsored International, Multi-Site Randomized
Crossover Trial of AHCL vs. 670G |
Martin de Bock, FRACP, Ph.D. |
New Zealand AHCL Randomized Crossover Trial (CE Mark Dataset) |
- “Simplifying Diabetes Management: Advancing Innovation Across
Outcomes, Patient Experience, and Support with the Guardian™
Connect Continuous Glucose Monitoring (CGM) System” on Sunday,
June 14, 3:00 – 3:45 p.m. CDT. Speakers to include:
Sean Salmon, president for the Diabetes Group at Medtronic |
Welcome & Overview |
Amit Bhargava, M.D. |
The Next Generation of Guardian™ Connect CGM: Accuracy When it
Matters Most with Real-World Outcomes |
Jason Baker, M.D. & his patient, Sam Talbot, celebrity chef,
author and entrepreneur |
Virtual Visit |
Scientific Presentations The following
16 poster and oral scientific data presentations represent the work
of Medtronic employees and independent investigators using
Medtronic devices in their research:Advanced Hybrid Closed Loop
(AHCL)
- “Safety and Glycemic Outcomes of the MiniMed Advanced Hybrid
Closed-Loop (AHCL) System in Subjects with T1D” – poster
presentation by Dr. Anders Carlson on Saturday, June 13 at
10:00 a.m. CDT.
- “Improved Technology Satisfaction and Sleep Quality with
Medtronic Minimed Advanced Hybrid Closed Loop Delivery Compared
with Predictive Low Glucose Suspend in People with Type 1 Diabetes
in a Randomized Crossover Trial” – poster presentation by
Olivia Collyns and Dr. Martin de Bock on Saturday, June 13 at 10:00
a.m. CDT.
- “Unannounced Meals at Home with The Medtronic Advanced Hybrid
Closed Loop” – poster presentation by Dr. Amir Tirosh on
Saturday, June 13 at 10:00 a.m. CDT.
- “Personalized Hybrid Closed-Loop Therapy Using a Digital Twin
in Patients with Type 1 Diabetes: At-Home Data” – poster
presentation by Benyamin Grossman on Saturday, June 13 at 10:00
a.m. CDT.
- “Six-Months At-Home Hybrid Closed-Loop vs. Manual Insulin
Delivery with Finger-Stick Blood Glucose Monitoring in Adults with
T1D: A Randomized Controlled Trial” – poster presentation by
David N. O’Neal on Saturday, June 13 at 10:00 a.m. CDT.
- “Improved Glycemic Outcomes with Medtronic MiniMed™ Advanced
Hybrid Closed-Loop Delivery: Results From a Randomized Crossover
Trial Comparing Automated Insulin Delivery With Predictive Low
Glucose Suspend in People with Type 1 Diabetes” – oral
presentation by Dr. Martin de Bock on Sunday, June
14 at 3:15 p.m. CDT.
- “Postprandial Glucose Control Ssing the Medtronic Advanced
Hybrid Closed-Loop System: Faster Acting Insulin Aspart (FiAsp) vs.
Insulin Aspart” – oral presentation by Dr. Melissa Lee and Dr.
David O’Neal on Sunday, June 14 at 5:15 p.m. CDT.
Extended Wear Infusion Set
- “Clinical Study of a New Extended Wear Infusion Set” –
poster presentation by Jacob Ilany and Ohad Cohen on Saturday, June
13 at 10:00 a.m. CDT.
- “CSII & Insulin: Does Extending the Wear Duration of
Infusion Sets Save Expensive Insulin?” – poster presentation
by Sarnath Chattaraj on Saturday, June 13 at 10:00 a.m. CDT.
- “Assessment of Adhesive Patches for an Extended-Wear Infusion
Set” – poster presentation by Gina Zhang on Saturday, June 13
at 10:00 a.m. CDT.
- “Testing a Novel Infusion Set for Extended Wear
Duration” – poster presentation by Dr. Bruce Buckingham on
Saturday, June 13 at 10:00 a.m. CDT.
- “Study of Insulin Stability Impact on Pump Therapy: Test Model
Development” – poster presentation by Sarnath Chattaraj on
Saturday, June 13 at 10:00 a.m. CDT.
Insulin Pump Therapy
- “A Feasibility Study Assessing the Accuracy of a Simplified
Meal-Time Bolus Calculation Option” – poster presentation by
Anirban Roy on Saturday, June 13 at 10:00 a.m. CDT.
- “Durable vs. Disposable Insulin Pumps for Type 1 Diabetes:
Health Care Costs and Utilization” – poster presentation by
Mona Shah on Saturday, June 13 at 10:00 a.m. CDT.
Multiple Daily Injections
- “Estimating an Optimal Meal Bolus for Persons with Diabetes on
Multiple Daily Injections without Carb Counting” – poster
presentation by Boyi Jiang on Saturday, June 13 at 10:00 a.m.
CDT.
Continuous Glucose Monitoring (CGM)
- “Detecting Dawn Phenomenon in T1D with Continuous Glucose
Monitoring and Activity Tracking” – poster presentation by
Sinu Bessy Abraham on Saturday, June 13 at 10:00 a.m. CDT.
Analyst and Investor
BriefingMedtronic will host a webcast to highlight its
Diabetes Group on Friday, June 12, from 5 p.m. to 6 p.m. CDT. The
webcast will feature remarks from Medtronic management, including
comments on Medtronic's clinical data, product pipelines, and
market outlooks. The live audio webcast can be accessed by clicking
on the Investor Events link
at http://investorrelations.medtronic.com on June 12.
Within 24 hours of the webcast, a replay will be available on the
same webpage. This event is not part of the official ADA
Scientific Sessions.
About the Diabetes Group at
Medtronic (www.medtronicdiabetes.com)Medtronic is
working together with the global community to change the way people
manage diabetes. The company aims to transform diabetes care by
expanding access, integrating care and improving outcomes, so
people living with diabetes can enjoy greater freedom and better
health.
About MedtronicMedtronic plc
(www.medtronic.com), headquartered in Dublin, Ireland, is among the
world's largest medical technology, services and solutions
companies - alleviating pain, restoring health and extending life
for millions of people around the world. Medtronic employs more
than 90,000 people worldwide, serving physicians, hospitals and
patients in more than 150 countries. The company is focused on
collaborating with stakeholders around the world to take healthcare
Further, Together.
Any forward-looking statements are subject to
risks and uncertainties such as those described in Medtronic's
periodic reports on file with the Securities and Exchange
Commission. Actual results may differ materially from anticipated
results.
-end-
Kendra CassilloPublic Relations+1-818-576-5611
Ryan WeispfenningInvestor Relations+1-763-505-4626
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024